News

Explore how model-informed drug development shapes ligelizumab's journey in treating chronic spontaneous urticaria, despite its eventual discontinuation.

Explore how dermatology-focused global medical missions can move beyond short-term “voluntourism” by fostering sustainable, collaborative partnerships that prioritize education, capacity building, and alignment with host country needs.

The study found that 59% of patients achieved IGA treatment success, surpassing other topical therapies.

Thermage FLX achieves 5 million treatments, showcasing its trusted non-surgical skin tightening technology for smoother, youthful skin.

In part 1 of this Case-Based Roundtable supplement, Seemal Desai, MD, FAAD; Ted Lain, MD, MBA, FAAD; and Pearl Grimes, MD, FAAD, discuss real-world vitiligo scenarios, offering diagnostic insights, therapeutic strategies, and practical pearls from their own experiences.

Sofia Wenzler, PhD, highlights the vital role dermatologists play in treating body-focused repetitive behaviors like skin picking and hair pulling.

Explore the latest strategies for managing CSU, including personalized therapies and updated 2025 guidelines for effective treatment.

Most physicians continue to prescribe topical corticosteroids despite prior treatment failure.

Vimal Prajapati, MD, FRCPC, DABD, highlighted key findings from the THRIVE-AA trials, noting the efficacy of deuruxolitinib 8 mg BID, its favorable safety profile, and its positioning alongside other JAK inhibitors.

EAACI's report highlights current practices and challenges in diagnosing and managing chronic urticaria in pediatric patients, emphasizing the need for improved education and resources.

Chesahna Kindred, MD, MBA, FAAD, highlights the need for tailored dermatological care for textured hair, addressing misdiagnoses and promoting collaboration with hairstylists.

COVID-19 significantly delayed melanoma diagnoses and treatments, leading to increased disease severity and advanced cases, highlighting urgent health care needs.

Arcutis Biotherapeutics seeks FDA approval for Zoryve cream to treat plaque psoriasis in children as young as 2, addressing a critical treatment gap.

While survival rates were similar across income levels, lower-income patients consistently presented with more aggressive disease.

Research shows it can take 7 to 10 years for individuals with HS to receive an accurate diagnosis.

Explore the latest insights on skin and scalp care, focusing on cultural sensitivity and early intervention for diverse dermatological needs.

Allergan Aesthetics has launched an initiative to educate on HA fillers, emphasizing safety and natural results, backed by expert insights and patient satisfaction data.

Discover how 529 plans empower dermatologists to save for college, offering tax benefits and new Roth IRA transfer options for added flexibility.

Happy Head's StrandIQ system revolutionizes hair loss treatment with personalized genetic analysis, enhancing hair growth and scalp health for individuals.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Vimal Prajapati, MD, FRCPC, DABD, reviews the mechanism of action, clinical trial outcomes, monitoring considerations, and safety profile of recently available deuruxolitinib.

Sofia Wenzler, PhD, addresses misconceptions about dermatillomania (skin picking) and trichotillomania (hair pulling), advocating for compassionate care and accessible treatment for BFRBs.

Explore effective strategies for managing CSU, including tailored therapies and the latest treatment advancements for optimal patient care.

Almirall and Absci enhance their collaboration, leveraging AI to revolutionize drug discovery for challenging dermatological conditions and improve patient outcomes.

The FDA cited concerns about patient population heterogeneity and confirmatory trial design.

Experts in Miami Beach emphasized that adherence often drives biologic choice more than efficacy in real-world psoriasis care.

Biofrontera Inc. advances acne treatment with aminolevulinic acid hydrochloride gel, completing a phase 2b study for moderate to severe cases.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of September.

Cases of dermatitis in workers and consumers alike show how allergen exposure transcends occupational boundaries.